Claims for Patent: 10,391,100
✉ Email this page to a colleague
Summary for Patent: 10,391,100
Title: | Combination of aurora kinase inhibitors and anti-CD20 antibodies |
Abstract: | The present invention relates to methods for the treatment of hematological malignancies. In particular, the invention provides methods for treatment of hematological malignancies by administering Aurora kinase inhibitors in combination with anti-CD20 antibodies. |
Inventor(s): | Manfredi; Mark (Newton, MA) |
Assignee: | Millennium Pharmaceuticals, Inc. (Cambridge, MA) |
Application Number: | 15/387,740 |
Patent Claims: | 1. A method of treating a human patient suffering from a hematological malignancy, comprising administering to the human patient an Aurora kinase inhibitor, wherein the
Aurora kinase inhibitor is 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin- -2-yl]amino}-2-methoxybenzoic acid, or a pharmaceutically acceptable salt thereof, simultaneously with or consecutively with an anti-CD20 antibody,
wherein the anti-CD20 antibody is rituximab, wherein the Aurora kinase inhibitor is administered to the human patient at a dose that is equivalent to an average daily dose (QD) in a mouse of about 3 mg/kg, and the anti-CD20 antibody is administered to
the human patient at a dose that is equivalent to an average weekly dose (QW) in a mouse of about 10 mg/kg.
2. The method of claim 1, wherein the hematological malignancy is selected from the group consisting of lymphoma, leukemia and multiple myeloma. 3. The method of claim 2, wherein the lymphoma is selected from the group consisting of B-cell lymphoma, Non-Hodgkin's lymphoma and mantle cell lymphoma. 4. The method of claim 1, wherein the human patient was treated previously with an anti-CD20 antibody. 5. The method of claim 1, wherein the Aurora kinase specific inhibitor is sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]ben- zazepin-2-yl]amino}-2-methoxybenzoate. |
Details for Patent 10,391,100
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2028-12-22 |
Genentech, Inc. | RITUXAN HYCELA | rituximab and hyaluronidase human | Injection | 761064 | 06/22/2017 | ⤷ Try a Trial | 2028-12-22 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.